Mounjaro Dominates India's GLP-1 Market, Sales Soar Past Rs 1000 Crore

• Eli Lilly's Mounjaro (tirzepatide) led the Indian pharmaceutical market in December 2025, with Rs 600 crore in total sales since its March launch.
• The GLP-1 agonists category, including Mounjaro, saw a 128% year-on-year jump, reaching Rs 1,170 crore in annual revenue by December 2025.
• Mounjaro achieved top sales despite limited insurance coverage, highlighting its rapid uptake and premium positioning.
• Obesity treatment is now an "established condition" in India, with Mounjaro widening the gap against first-generation GLP-1 therapies.
• Future growth is expected from partnerships (Eli Lilly-Cipla, Novo Nordisk-Emcure) and branded generics entering the market from March 2026.

Why It Matters: Mounjaro spearheads the booming GLP-1 market in India, with generics set to further expand access and consumption.